Greenway creates Interop U

EHR vendor Greenway Health has developed Greenway Interoperability University to recruit and train people to become interoperability experts.

The six-week, on-the-job program features a combination of classroom instruction, hands-on exercises, assessments, mentor shadowing and ongoing learning, according to a release. Students, many of whom are recent college graduates, are trained by interoperability experts who have many years of experience.

The first two classes recently held their graduation ceremony at the company’s Carrollton, Georgia headquarters. 

“Bottom line, lives are at risk when health IT systems don’t talk to each other,” said Greenway CEO Tee Green. “That’s why Greenway Health has long been a leader in driving interoperability and enabling data liquidity. ‘Interop U’ is yet another way we’re accelerating innovation in this fundamental area while creating rewarding career paths for people interested in the wide-open field of information technology.”

Greenway Health is a founding member of CommonWell Health Alliance, the first ambulatory health IT solution provider to join the eHealth Exchange and, this spring, was one of only three HIT companies in the new Surescripts National Record Locator service. 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.